StockNews.AI
MCRB
StockNews.AI
168 days

Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025

1. Seres Therapeutics will host a financial results call on March 13, 2025. 2. Company developed VOWST™, the first orally administered microbiome therapeutic. 3. SER-155 is in development with Breakthrough Therapy designation for specific patient populations. 4. SER-155 shows promise in reducing bloodstream infections in vulnerable patient groups. 5. Upcoming call may provide insights into financial health and future strategies.

Earnings
-8.04%Current Return
VS
-0.75%S&P 500
$0.748703/04 07:05 AM EDTEvent Start
$0.688503/05 01:23 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

The successful development and designation of SER-155 enhances MCRB's market potential, similar to prior initiatives that bolstered share value. For instance, the approval of VOWST led to a significant increase in stock performance due to heightened investor confidence.

How important is it?

The article highlights significant advancements in product development and regulatory designations, which strongly correlate with MCRB's financial and operational viability.

Why Short Term?

The upcoming financial results call could lead to immediate market reactions, echoing past patterns when firms announce clinical progress or financial achievements. Previous results calls have led to volatile trading moments for biotech firms.

Related Companies

NESTLÉABT
March 04, 2025 07:00 ET  | Source: Seres Therapeutics, Inc. CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) --  Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on March 13, 2025 at 8:30 a.m. ET to discuss fourth quarter and full year 2024 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 6331602. To join the live webcast, please visit the “Investors and News” section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days. About Seres TherapeuticsSeres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has received Breakthrough Therapy designation for the reduction of bloodstream infections in adults undergoing allo-HSCT and Fast Track designation for reducing the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT, and which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT. SER-155 and the Company's other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation, rather than from the donor-sourced production process used for VOWST. In addition to allo-HSCT, the Company intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically vulnerable patient populations including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. For more information, please visit www.serestherapeutics.com. Investor and Media Contact:  IR@serestherapeutics.com Carlo Tanzi, Ph.D.Kendall Investor Relationsctanzi@kendallir.com

Related News